News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

STADA Pharmaceuticals In Talks With Spirig Pharma Ltd. About Purchase Of Generics Operations


5/23/2011 8:10:49 AM

Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain drugs.

Its fellow German pharma company Stada is looking to acquire a portfolio of Grunenthal’s branded drugs that would include the pain treatments Tramadol, Zaldiar and Transtec.

Also on the table is Palexia, Grunenthal’s novel first-in-class painkiller, which is expected to make annual sales of up to 25 million euros, but this has not yet been factored into the deal price.




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES